P

PellePharm

50 employees

PellePharm develops patidegib, a novel hedgehog pathway inhibitor to mitigate the tumor burden in patients with basal cell carcinomas.

Basic info

Industry

biotechnology research

Sectors

Medical Device
Biotechnology
Gorlin Syndrome
rare disease
dermatology
Biotech
Dermatological Diseases
Therapeutics
Basal Cell Carcinoma
Hedgehog Signaling
pharmaceuticals

Date founded

2016

Funding rounds raised

Total raised

$20M

from 1 investors over 1 rounds

P

PellePharm raised $20M on August 1, 2017

Investors: BridgeBio

FAQ